Factors Affecting Biochemical Recurrence of Prostate Cancer

by U.S. Medicine

September 18, 2017

DURHAM, NC—What is the association between lowest prostate-specific antigen (PSA) and time to nadir with biochemical recurrence (BCR) risk after radical prostatectomy (RP)?

A study published recently in the journal Urology used the SEARCH database to try to answer that question.1

Durham, NC, VAMC researchers and colleagues performed a retrospective analysis of 1,939 men from the SEARCH database treated with RP between 1998-2015 with available ultrasensitive PSA nadir within one to six after RP.

Results indicated that, among men with an undetectable PSA nadir, the TTN was unrelated to BCR—1-2.9 vs. 3-6 months for a hazard ratio of 0.86. Despite TTN, men with detectable nadir had increased risk of BCR—TTN 3-6 months: HR 1.81; TTN 1-2.99 months: HR 3.75 vs. undetectable nadir and TTN 3-6 months, the study noted.

The findings also suggested that, among men with a detectable PSA at 1-3 months, 53% had a lower follow-up PSA three to six months after RP which was undetectable in 32% and lower but still detectable in 21%.

“In the post-RP setting, men with both a detectable nadir and a shorter TTN had an increased risk of BCR. Intriguingly, about half of the men with a detectable PSA in the first 3 months after RP had a lower follow-up PSA between 3 and 6 months after RP,” study authors concluded. “If confirmed in future studies, this has important implications for patients considering adjuvant therapy based upon post-operative PSA values in the first 3 months after RP.”

1.    Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moreira DM, Freedland SJ. Timing of PSA Nadir after Radical Prostatectomy and Risk of Biochemical Recurrence. Urology. 2017 Jul 19. pii: S0090-4295(17)30742-2. doi: 10.1016/j.urology.2017.07.009. [Epub ahead of print] PubMed PMID: 28735016.


Related Articles

Side-effects Differ Between Radiation Therapies for Prostate Cancer

A recent study compared patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer.

Parkinson’s Drug Not Associated With Higher Prostate Cancer Risk

An increased incidence of prostate cancer was observed in Parkinson's disease (PD) patients treated with entacapone during a pre-approval randomized clinical trial, according to a new study which noted that the relationship had not yet been intensely investigated.

U.S. Medicine Recommends

More From department of veterans affairs

Department of Veterans Affairs (VA)

VHA Makes Progress in Improving Safety of Opioid Prescribing

VHA medical facilities should ensure that its providers are following three key opioid risk mitigation strategies, including conducting urine drug screening, a recent report recommended.

Department of Veterans Affairs (VA)

VA faces healthcare staffing shortages, barriers to hiring facility leaders

A facility-specific survey found that 138 of 140 VA facilities reported shortages of medical officers, with psychiatry and primary care positions being the most frequently listed.

Department of Veterans Affairs (VA)

Veteran nephrologist labors to improve ESRD treatment at VA

When Terrence O’Neil, MD, retired as chief of nephrology at the James H. Quillen VAMC in Johnson City in December 2016, he left in his wake decades of work treating kidney disease—nearly 35 years in the Air Force and DoD, plus 11 more at VA.

Department of Veterans Affairs (VA)

Committee approves bill to provide agent orange benefits to ‘blue water’ vets

A long sought-after bill that would make it easier for Blue Water Navy veterans to receive Agent Orange benefits has been passed by a key House of Representatives committee.

Department of Veterans Affairs (VA)

Bill to Streamline, Expand VA’s Choice Program Signed Into Law

Legislation that would streamline VA’s community care programs into one program and expand VA’s caregiver program to veterans of all eras was signed into law earlier this month..

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up